Loading...
XNYSAXP
Market cap210bUSD
Dec 20, Last price  
298.65USD
1D
1.90%
1Q
11.03%
Jan 2017
303.15%
Name

American Express Co

Chart & Performance

D1W1MN
XNYS:AXP chart
P/E
25.12
P/S
3.49
EPS
11.89
Div Yield, %
0.85%
Shrs. gr., 5y
-3.04%
Rev. gr., 5y
8.40%
Revenues
60.36b
+14.19%
28,248,000,00023,347,000,00025,900,000,00027,731,000,00028,365,000,00024,523,000,00027,819,000,00029,962,000,00031,582,000,00032,974,000,00034,292,000,00032,818,000,00032,119,000,00033,471,000,00040,338,000,00043,556,000,00036,087,000,00042,380,000,00052,862,000,00060,363,000,000
Net income
8.37b
+11.45%
3,445,000,0003,734,000,0003,707,000,0004,012,000,0002,699,000,0002,130,000,0004,057,000,0004,935,000,0004,482,000,0005,359,000,0005,885,000,0005,163,000,0005,408,000,0002,736,000,0006,921,000,0006,759,000,0003,135,000,0008,060,000,0007,514,000,0008,374,000,000
CFO
18.56b
-11.96%
9,143,000,0008,045,000,0009,005,000,0008,484,000,0008,666,000,0006,384,000,0009,288,000,00010,475,000,0007,082,000,0008,547,000,00010,990,000,00010,972,000,0008,224,000,00013,540,000,0008,930,000,00013,632,000,0005,591,000,00014,645,000,00021,079,000,00018,559,000,000
Dividend
Oct 04, 20240.7 USD/sh
Earnings
Jan 24, 2025

Profile

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
URL
https://www.americanexpress.com/
IPO date
May 18, 1977
Employees
77,300
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
60,363,000
14.19%
52,862,000
24.73%
42,380,000
17.44%
Cost of revenue
39,131,000
32,824,000
30,446,000
Unusual Expense (Income)
NOPBT
21,232,000
20,038,000
11,934,000
NOPBT Margin
35.17%
37.91%
28.16%
Operating Taxes
2,139,000
2,071,000
2,629,000
Tax Rate
10.07%
10.34%
22.03%
NOPAT
19,093,000
17,967,000
9,305,000
Net income
8,374,000
11.45%
7,514,000
-6.77%
8,060,000
157.10%
Dividends
(1,780,000)
(1,565,000)
(1,448,000)
Dividend yield
1.29%
1.41%
1.12%
Proceeds from repurchase of equity
(3,622,000)
(3,446,000)
(9,188,000)
BB yield
2.63%
3.10%
7.11%
Debt
Debt current
1,293,000
1,000,000
2,000,000
Long-term debt
47,866,000
43,003,000
39,014,000
Deferred revenue
3,027,000
2,516,000
Other long-term liabilities
(47,866,000)
156,066,000
(14,000)
Net debt
(36,915,000)
929,000
13,980,000
Cash flow
Cash from operating activities
18,559,000
21,079,000
14,645,000
CAPEX
(1,563,000)
(1,855,000)
(1,550,000)
Cash from investing activities
(24,433,000)
(33,689,000)
(10,529,000)
Cash from financing activities
18,379,000
24,509,000
(14,933,000)
FCF
(43,635,000)
17,740,000
41,215,000
Balance
Cash
86,074,000
38,074,000
24,034,000
Long term investments
5,000,000
3,000,000
Excess cash
83,055,850
40,430,900
24,915,000
Stockholders' equity
16,685,000
39,822,000
43,046,000
Invested Capital
245,716,000
172,496,000
151,921,000
ROIC
9.13%
11.08%
7.30%
ROCE
8.09%
9.37%
6.75%
EV
Common stock shares outstanding
736,000
752,000
790,000
Price
187.34
26.80%
147.75
-9.69%
163.60
35.31%
Market cap
137,882,240
24.10%
111,108,000
-14.03%
129,244,000
32.62%
EV
100,967,240
138,641,000
175,588,000
EBITDA
22,883,000
21,664,000
13,629,000
EV/EBITDA
4.41
6.40
12.88
Interest
6,849,000
2,763,000
1,283,000
Interest/NOPBT
32.26%
13.79%
10.75%